Alberto Cruz-Bermúdez

16PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsMetabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 21, 2026
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer.

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|Dec 23, 2025
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Mariano Provencio, Begoña Campos, María Guirado

|Oct 20, 2024
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.

Marta Molina-Alejandre, Francisco Perea, Virginia Calvo

|Jun 28, 2023
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Mariano Provencio, Ernest Nadal, José L González-Larriba

Pageof 3

Frequent Collaborators

9 joint publications

Mariano Provencio Pulla

8 joint publications

Atocha Romero

8 joint publications

Ernest Nadal

7 joint publications

Alex Martínez-Martí